Business Wire

SES/IMS

Share
IMS and SES to Expand Internet Connectivity to Underserved Colombian Communities With O3b mPOWER

SES’s satellite-based trunking services will enable leading Colombian fibre optic networks service provider Integra Multisolutions (IMS) to extend and enhance fibre-like connectivity for Colombian municipalities with fewer than 100,000 inhabitants located out of the reach of terrestrial infrastructure, SES announced today. The new service will begin on SES’s O3b medium earth orbit (MEO) constellation and later migrate onto O3b mPOWER, SES’s next-generation MEO system, in 2022 when service will expand to additional cities.

The first site to be connected will be Puerto Leguizamo, a municipality located in the Putumayo Department in the southern border region of the country. SES and IMS will go on to deliver service to other sparsely populated cities across Colombia that experience poor or inconsistent connectivity services.

SES’s Trunk mPOWERED service will equip IMS to enable local Internet service providers to serve a combination of enterprise, residential, MNO and civilian government projects. IMS is among the first companies in Latin America to sign up for the O3b mPOWER system, which can deliver low-latency, high-speed, uncontended services from tens of megabits to multiple gigabits per second to a single site.

According to the Colombian Ministry of Telecommunications, fixed broadband subscriptions in the country reached 8.22 million in 2021, which translates to 16.10 subscriptions per 100 people. However, the National Administrative and Statistics Department (Dane) revealed earlier this year the results of the Survey of Information and Communication Technologies in Households (ENTIC Hogares) showing only 56.5% of the households surveyed have an internet connection. The survey identified an important difference between households in the main cities, where 66.6% have internet access, and those in rural and dispersed areas, where only 23.9% of the households do. The Putumayo Department is among the regions with challenges to access reliable connectivity services.

“By working together with SES, we are able to quickly and cost-effectively expand our network in underserved and tough-to-reach areas helping to address the digital divide for these communities,” said Juan Carlos Hernandez Mendoza, CEO of IMS Group. “Our goal is to provide our end users the best quality of service across Colombia, which means access to high-performing services at all times, no matter where they are. The capabilities of the proven O3b MEO fleet, and the scalability and flexibility of the upcoming O3b mPOWER services combined with SES satellite network and IMS fibre optics networks expertise, allow us to achieve exactly that.”

“Our multi-orbit satellite solutions have been bringing reliable connectivity services across Colombia for almost 10 years,” said Omar Trujillo, Americas Vice President of Fixed Data Sales at SES. “We are delighted to partner with IMS to extend terrestrial networks with the revolutionary capabilities of the O3b mPOWER constellation and deliver fibre-like Internet access to Colombians wherever they live.”

Follow us on:
TwitterFacebookYouTubeLinkedInInstagram
Read our Blogs >
Visit the Media Gallery >

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,500 channels and has an unparalleled reach of 361 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .

About IMS

IMS was created in 2016, since then IMS is becoming the main PARTNER for all the small and medium Internet Service Providers in Colombia through terrestrial telecom technologies specialized in fiber optic networks, Networking Engineering, ISP Tech Solutions, supply chain, and many more. Currently IMS has more than 100,000 kilometres of available fiber throughout Colombia and sells more than 300 Gbps of fiber optic capacity to more than 250 corporate customers, becoming a very important provider for internet carriers in the region. For more information about IMS go to www.ims.net.co .

Link:

ClickThru

Social Media:

https://www.facebook.com/SES.Satellites/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye